3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
103
Carcinoma, Renal Cell
70
Neoplasm Metastasis
48
Neoplasms
37
Neuroendocrine Tumors
33
Kidney Neoplasms
27
Recurrence
19
Tuberous Sclerosis
18
Carcinoma, Non-Small-Cell Lung
17
Prostatic Neoplasms
16
Triple Negative Breast Neoplasms
15
Lymphoma
15
Lymphoma, Mantle-Cell
14
Lymphoma, Large B-Cell, Diffuse
14
Head and Neck Neoplasms
14
Glioblastoma
14
Colorectal Neoplasms
13
Carcinoma, Hepatocellular
13
Stomach Neoplasms
12
Lung Neoplasms
12
Leukemia, Lymphocytic, Chronic, B-Cell
12
Hodgkin Disease
12
Brain Neoplasms
12
Sarcoma
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Pancreatic Neoplasms
11
Glioma
11
Waldenstrom Macroglobulinemia
10
Lymphoma, Follicular
10
Carcinoma, Neuroendocrine
10
Interventions
Megestrol Acetate
7
Medroxyprogesterone Acetate
4
Progestins
3
Metformin
3
Tirzepatide
2
Progesterone
2
Letrozole
2
Biopsy
2
Atorvastatin
2
semaglutide
1
ricin A-GnRH conjugate
1
exemestane
1
estradiol, norethindrone drug combination
1
Tamoxifen
1
Rosuvastatin Calcium
1
Resistance Training
1
Pterocarpus marsupium
1
Pharmacogenomic Variants
1
Nutrition Assessment
1
Magnetic Resonance Spectroscopy
1
Levonorgestrel
1
LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)-
1
Hysteroscopy
1
Hysterectomy
1
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
Gonadotropin-Releasing Hormone
1
Genetic Testing
1
Everolimus
1
Estrogen Replacement Therapy
1
Cyproterone acetate, ethinyl estradiol drug combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Endometrial Hyperplasia
×
Everolimus
×
Clear all
NCT02397083
2026-02-13
LEVER
M.D. Anderson Cancer Center
Phase 2
Active not recruiting
102 enrolled